Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D09WYL
|
||||
| Former ID |
DIB010428
|
||||
| Drug Name |
GSK-557296
|
||||
| Synonyms |
Epelsiban; Epelsiban besylate; Premature ejaculation therapeutic (oral), GlaxoSmithKline
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Premature ejaculation [ICD9: 302.75; ICD10:F52.4] | Phase 2 | [1] | ||
| Company |
GlaxoSmithKline plc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C30H38N4O4
|
||||
| Canonical SMILES |
C1CN(CCO1)C(=O)[C@H](N1[C@@H](C(=O)N[C@@H](C1=O)C1Cc2c(<br />C1)cccc2)[C@@H](C)CC)c1c(nc(cc1)C)C
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Oxytocin receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Oxytocin signaling pathway | |||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| PANTHER Pathway | Oxytocin receptor mediated signaling pathway | ||||
| Reactome | Vasopressin-like receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Myometrial Relaxation and Contraction Pathways | |||||
| Oxytocin signaling | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01021553) A Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Study in Men With Premature Ejaculation. U.S. National Institutes of Health. | ||||
| REF 2 | Inhibition of ejaculation by the non-peptide oxytocin receptor antagonist GSK557296: a multi-level site of action. Br J Pharmacol. 2013 Aug;169(7):1477-85. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.